// App-Quantinova.ai

665 : JAVELIN Bladder Medley: a phase 2 trial of avelumab in combination with other antitumor drugs as first-line maintenance therapy for advanced urothelial carcinoma

Researchers

Presenter

  • Jean Hoffman-Censits

Principal Investigators

  • Petros Grivas

  • Thomas Powles

  • Danko Martincic

  • Jessica Hawley

  • Karin Tyroller

  • Sonja Seeberger

  • Silke Guenther

  • Natalia Jacob

  • Keyvan Tadjalli Mehr

  • Noah Hahn

Medical Centers

  • The healthcare business of Merck KGaA, Darmstadt, Germany

  • Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St Bartholomews Hospital, London, United Kingdom

  • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins Medical Institutions, Baltimore, MA, USA

  • EMD Serono, Billerica, MA, USA

  • University of Washington and Fred Hutchinson Cancer Center, Seattle, WA

  • Beacon Cancer Care, Coeur d’Alene, ID, USA

  • Division of Oncology, Department of Medicine, University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA

  • Johns Hopkins University Greenberg Bladder Cancer Institute, Baltimore, MD

Locations

  • Germany

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Advanced Urothelial Carcinoma

Biomarkers

  • Interleukin-15

Drug/Treatment

  • sacituzumab govitecan

  • IMMU132

  • Carboplatin

  • Gemcitabine

  • Cisplatin

  • Avelumab

  • IL-15

Outcome

  • N/A

Study Design

  • Randomized

  • Pharmacokinetics

  • Open Label

  • Multicenteric

Phase

  • II

Study Id's

  • NCT05327530

Sponsors

  • The Healthcare Business of Merck KGaA

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved